Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.
about
Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.Signature-tagged mutagenesis in a chicken infection model leads to the identification of a novel avian pathogenic Escherichia coli fimbrial adhesinAdhesive threads of extraintestinal pathogenic Escherichia coli.Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesinUrethral obstruction of 6 hours or less causes bacteriuria, bacteremia, and pyelonephritis in mice challenged with "nonuropathogenic" Escherichia coliUrinary tract infections in children. An update.Adhesins as targets for vaccine development.Interactive surface in the PapD chaperone cleft is conserved in pilus chaperone superfamily and essential in subunit recognition and assembly.Serum immunoglobulin response and protection from homologous challenge by Proteus mirabilis in a mouse model of ascending urinary tract infection.Analysis of the F antigen-specific papA alleles of extraintestinal pathogenic Escherichia coli using a novel multiplex PCR-based assay.The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.Epitopes of Escherichia coli alpha-hemolysin: identification of monoclonal antibodies that prevent hemolysisCharacteristics and prevalence within serogroup O4 of a J96-like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papG.A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract.Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development.Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.Frequency and organization of papA homologous DNA sequences among uropathogenic digalactoside-binding Escherichia coli strains.The multifunctional protein YdiV represses P fimbria-mediated adherence in uropathogenic Escherichia coli.Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse modelDNA sequences of three papA genes from uropathogenic Escherichia coli strains: evidence of structural and serological conservation.Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infectionThe sweet connection: Solving the riddle of multiple sugar-binding fimbrial adhesins in Escherichia coli: Multiple E. coli fimbriae form a versatile arsenal of sugar-binding lectins potentially involved in surface-colonisation and tissue tropism.Susceptibility to acute pyelonephritis or asymptomatic bacteriuria: host-pathogen interaction in urinary tract infections.Attenuation of antibody response to acute pyelonephritis by treatment with antibiotics.
P2860
Q30403958-12797C81-AFC3-4874-851B-11FCC0623215Q30882970-AC347C1E-7714-4952-8BD3-8C82B9D5F48AQ33554744-8C0A2B1B-B8CF-4C31-82D7-D949799352D8Q33556727-B174B421-C224-4BCA-A566-F2568B32D8A3Q33605438-46A91329-3DF0-4A07-97DA-5D9F7C3775C8Q33606769-E62CF87F-7334-49B5-B666-C1FFF31F0A5AQ33643106-6674712D-3D26-4165-A34D-FCCF6829ADEBQ33938565-F8EA6D40-B098-46C7-97EE-DC84D47FCE96Q34002879-CA980317-B49F-4A85-9AF1-F3B996D59B46Q34003677-711C96A2-6505-4130-9D12-C3811975A249Q34943892-F669A786-5AFD-4F95-9BA3-025D87B892DBQ35104471-252E361A-AAD5-4C2A-8C8B-7B88E1D9D59EQ35548826-65937DD4-5429-47A0-9819-E35B32712BEFQ35878788-FC668679-E1FC-4AD4-84DE-2A444986BAF7Q35945819-5381E7B9-D8B7-4EEC-95BC-CBEAD95C299BQ36383799-A88A63F2-D75C-4C53-B1F7-DDDC5354B225Q36951570-86ACB64B-EB6F-480E-A1D7-C6870A6B52CFQ36965100-90EB5F67-5383-4B60-9289-428EE3FAD5D1Q36970935-8121CB22-EFBD-49D8-94F1-9ECF1FAA9F7FQ36974898-B9D98F1D-8870-40E9-B3FA-8EC9AE20782EQ36988356-B0771764-57EF-4E23-B9BC-B4F17EC17C07Q36988565-7601A7DA-01E2-408C-8330-E34F01CDA7B4Q37371765-09276BE8-54A0-4B11-9A46-6BBC059F4FECQ37846185-4200FECC-409C-4951-9AE2-BA124C54F4B0Q37983470-E58167C5-E7CE-4282-A20B-BF8D66FB564DQ40088038-3AD369FD-A742-4A83-8181-5E620EFA8275
P2860
Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
name
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@ast
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@en
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@nl
type
label
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@ast
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@en
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@nl
prefLabel
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@ast
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@en
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@nl
P2093
P2860
P356
P1476
Gal-Gal pili vaccines prevent ...... gous piliated E. coli strains.
@en
P2093
P2860
P304
P356
10.1172/JCI114123
P407
P577
1989-06-01T00:00:00Z